New pill shows promise against tough prostate cancer

NCT ID NCT01171898

Completed Disease control Sponsor: Aragon Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called ARN-509 in 127 men with advanced prostate cancer that had stopped responding to standard hormone therapy. The goal was to find a safe dose and see if the drug could lower PSA levels, a marker of cancer activity. The drug works by blocking male hormones that fuel cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ARN-509 (apalutamide), a drug that blocks male hormones that fuel prostate cancer growth
What this could lead to: If successful, this could lead to a new oral treatment option for men with advanced prostate cancer that no longer responds to standard hormone therapy.
What could go wrong: This is an early-phase trial with a small number of participants, so the drug may not prove effective or safe in larger studies. Side effects and limited benefit are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Study site

San Diego, California, United States
Study site

San Francisco, California, United States
Study site

Atlanta, Georgia, United States
Study site

Baltimore, Maryland, United States
Study site

Boston, Massachusetts, United States
Study site

Ann Arbor, Michigan, United States
Study site

Omaha, Nebraska, United States
Study site

New York, New York, United States
Study site

Raleigh, North Carolina, United States
Study site

Portland, Oregon, United States
Study site

Lancaster, Pennsylvania, United States
Study site

Myrtle Beach, South Carolina, United States
Study site

Dallas, Texas, United States
Study site

Seattle, Washington, United States
Study site

Madison, Wisconsin, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.